The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secr...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/10/1534 |
id |
doaj-ea346be043884249baa7de9f9a755161 |
---|---|
record_format |
Article |
spelling |
doaj-ea346be043884249baa7de9f9a7551612020-11-25T01:42:23ZengMDPI AGJournal of Clinical Medicine2077-03832019-09-01810153410.3390/jcm8101534jcm8101534The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 TherapyAntje Tunger0Ulrich Sommer1Rebekka Wehner2Anne Sophie Kubasch3Marc-Oliver Grimm4Michael Philipp Bachmann5Uwe Platzbecker6Martin Bornhäuser7Gustavo Baretton8Marc Schmitz9National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyInstitute of Pathology, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyNational Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyMedical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Liebigstraße 22, 04103 Leipzig, GermanyDepartment of Urology, Jena University Hospital, Lessingstraße 1, 07743 Jena, GermanyNational Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyMedical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Liebigstraße 22, 04103 Leipzig, GermanyNational Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyNational Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyNational Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, GermanyThe administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secretion, and cytotoxic activity of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, resulting in enhanced antitumor responses. Anti-PD-1 or anti-PD-L1 therapy has induced tumor regression and improved clinical outcome in patients with different tumor entities, including melanoma, non-small-cell lung cancer, and renal cell carcinoma. These findings led to the approval of various anti-PD-1 or anti-PD-L1 antibodies for the treatment of tumor patients. However, the majority of patients have failed to respond to this treatment modality. Comprehensive immune monitoring of clinical trials led to the identification of potential biomarkers distinguishing between responders and non-responders, the discovery of modes of treatment resistance, and the design of improved immunotherapeutic strategies. In this review article, we summarize the evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy.https://www.mdpi.com/2077-0383/8/10/1534cancer immunotherapyimmune monitoringimmune checkpointsprogrammed cell death protein 1programmed cell death 1 ligand 1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antje Tunger Ulrich Sommer Rebekka Wehner Anne Sophie Kubasch Marc-Oliver Grimm Michael Philipp Bachmann Uwe Platzbecker Martin Bornhäuser Gustavo Baretton Marc Schmitz |
spellingShingle |
Antje Tunger Ulrich Sommer Rebekka Wehner Anne Sophie Kubasch Marc-Oliver Grimm Michael Philipp Bachmann Uwe Platzbecker Martin Bornhäuser Gustavo Baretton Marc Schmitz The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy Journal of Clinical Medicine cancer immunotherapy immune monitoring immune checkpoints programmed cell death protein 1 programmed cell death 1 ligand 1 |
author_facet |
Antje Tunger Ulrich Sommer Rebekka Wehner Anne Sophie Kubasch Marc-Oliver Grimm Michael Philipp Bachmann Uwe Platzbecker Martin Bornhäuser Gustavo Baretton Marc Schmitz |
author_sort |
Antje Tunger |
title |
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
title_short |
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
title_full |
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
title_fullStr |
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
title_full_unstemmed |
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
title_sort |
evolving landscape of biomarkers for anti-pd-1 or anti-pd-l1 therapy |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2019-09-01 |
description |
The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secretion, and cytotoxic activity of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, resulting in enhanced antitumor responses. Anti-PD-1 or anti-PD-L1 therapy has induced tumor regression and improved clinical outcome in patients with different tumor entities, including melanoma, non-small-cell lung cancer, and renal cell carcinoma. These findings led to the approval of various anti-PD-1 or anti-PD-L1 antibodies for the treatment of tumor patients. However, the majority of patients have failed to respond to this treatment modality. Comprehensive immune monitoring of clinical trials led to the identification of potential biomarkers distinguishing between responders and non-responders, the discovery of modes of treatment resistance, and the design of improved immunotherapeutic strategies. In this review article, we summarize the evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy. |
topic |
cancer immunotherapy immune monitoring immune checkpoints programmed cell death protein 1 programmed cell death 1 ligand 1 |
url |
https://www.mdpi.com/2077-0383/8/10/1534 |
work_keys_str_mv |
AT antjetunger theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT ulrichsommer theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT rebekkawehner theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT annesophiekubasch theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT marcolivergrimm theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT michaelphilippbachmann theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT uweplatzbecker theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT martinbornhauser theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT gustavobaretton theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT marcschmitz theevolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT antjetunger evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT ulrichsommer evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT rebekkawehner evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT annesophiekubasch evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT marcolivergrimm evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT michaelphilippbachmann evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT uweplatzbecker evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT martinbornhauser evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT gustavobaretton evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy AT marcschmitz evolvinglandscapeofbiomarkersforantipd1orantipdl1therapy |
_version_ |
1725036847754641408 |